<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Clinical and Experimental Medicine</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/464D389D-37E8-4F35-8E73-3DE6F1D2DA17"><gtr:id>464D389D-37E8-4F35-8E73-3DE6F1D2DA17</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Harvey</gtr:otherNames><gtr:surname>Adams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/438CF1E1-40A8-469C-995E-CBDE54B96F74"><gtr:id>438CF1E1-40A8-469C-995E-CBDE54B96F74</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:otherNames>Olive</gtr:otherNames><gtr:surname>Savage</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E8EE1BC9-799D-4921-8C12-8689B9552A74"><gtr:id>E8EE1BC9-799D-4921-8C12-8689B9552A74</gtr:id><gtr:firstName>Jon</gtr:firstName><gtr:surname>Frampton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/16B653E2-0DEA-4EC3-BEB0-B755754726BD"><gtr:id>16B653E2-0DEA-4EC3-BEB0-B755754726BD</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Buckley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2A9A0613-B093-4400-A3DF-A5FC7A6293B5"><gtr:id>2A9A0613-B093-4400-A3DF-A5FC7A6293B5</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:surname>Egginton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/10E90197-CBD0-44C6-87F3-BB70B9925612"><gtr:id>10E90197-CBD0-44C6-87F3-BB70B9925612</gtr:id><gtr:firstName>Gerard</gtr:firstName><gtr:surname>Nash</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/29EC988F-DB6A-423F-8A8F-81077E88E2EE"><gtr:id>29EC988F-DB6A-423F-8A8F-81077E88E2EE</gtr:id><gtr:firstName>George</gtr:firstName><gtr:otherNames>Edward</gtr:otherNames><gtr:surname>Rainger</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BF2367AE-4C80-4EB1-9BA3-62D366178A0E"><gtr:id>BF2367AE-4C80-4EB1-9BA3-62D366178A0E</gtr:id><gtr:firstName>Steve</gtr:firstName><gtr:surname>Watson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2B0F97E4-31D8-4D0A-9F3D-BCBF30B574C5"><gtr:id>2B0F97E4-31D8-4D0A-9F3D-BCBF30B574C5</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Wakelam</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0300102"><gtr:id>5989A480-C8FD-4E8F-9FB7-5AF5A6F7BDD5</gtr:id><gtr:title>Adhesion receptors in the vasculature: from mouse to human</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0300102</gtr:grantReference><gtr:abstractText>PUBLIC ENGAGEMENT IN SCIENCE. This application brings together nine research groups, three of which are headed by clinicians, to investigate various aspects of the blood vasculature in health and disease. Each group has expertise in distinct but complementary areas of research and bringing them together through the formation of an MRC co-operative group has several advantages including (i) added value that will come from closer interactions and shared expertise within the co-operative group; (ii) a reduction in research costs through sharing of materials and equipment; and, most importantly, (iii) the opportunity to take on more complex scientific problems. The co-operative will focus on vascular diseases including atherosclerosis, thrombosis and the generation of new blood vessels in cancer and tissue repair. In addition the role of the vasculature in inflammatory disease will be studied in the context of direct damage to blood vessels (vasculitis) or conditions where inflammation occurs in tissues as a consequence of inappropriate recruitment of inflammatory cells from the blood (inflammatory liver disease and rheumatoid arthritis). These diseases are all caused by defects in the same types of vascular cells including white blood cells, endothelial cells (which line the blood vessel) and platelets. Thus, the knowledge of one research group in the role of a particular disease or cell type will be readily applicable to that of another. The bringing together of clinically-based and basic research groups with complementary expertise in related areas will enable us to define the molecular mechanisms of vascular physiology and pathology and thereby to provide important new insights into disease processes which are a major health burden on society.</gtr:abstractText><gtr:technicalSummary>This is a request to establish an MRC Co-operative Group at the University of Birmingham to investigate the role of adhesion molecules and their receptors within the vasculature in health and disease. The co-operative will be made up of three clinical groups with active research laboratories and six basic science groups with expertise in a variety of vascular cells including endothelial cells, haematopoietic cell precursors, fibroblasts, lymphocytes, mast cells, megakaryocytes, neutrophils, platelets and smooth muscle. Seven of these groups already have a strong track record of collaboration and interaction in Birmingham and have played a major role in establishing an international reputation for the University in the field of adhesion events in the vasculature. The arrival of Watson and Frampton from Oxford builds on this by bringing skills in mouse genetics, a strengthening of intracellular signalling and provision of complementary expertise in platelets and thrombosis. Eight of these groups, and part of the ninth group, will relocate to two new research facilities, the Institute of Biomedical Research (IBR) and the adjacent Cardiovascular Link Building (CLB), in the autumn of 2003 thereby providing a further impetus to the formation of the co-operative grouping. Several of the members of the co-operative are also part of The MRC Centre for Immune Regulation which will move to the IBR at this time. The theme of this application is highly complementary to the work of the MRC Centre and both groups will benefit from their close proximity and overlapping interests.</gtr:technicalSummary><gtr:fund><gtr:end>2009-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>302720</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BHF supporters meeting - Birmingham</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9115383F-0DC4-4DBF-A3E4-C171877CD272</gtr:id><gtr:impact>Overview of cardiovascular research and how supporters fundraising helps with research

Feedback was incredibly positive, the lab tour was a particular success. Supporters found out about how we are fighting cardiovascular disease in Birmingham and how their fundraising is helping our research; it gave them even more of an incentive to help the BHF and made them feel proud to see how their hard work fundraising has achieved.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2009,2014,2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1246548</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Programme Grant (The early events in signalling by platelet ITAM and ITAM-like receptors)</gtr:description><gtr:end>2014-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>C0B4FDE7-DD0A-4E4E-BE76-81DFEA97A429</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7ECE84D5-4E53-41B1-B90A-ECA5B2DBA570"><gtr:id>7ECE84D5-4E53-41B1-B90A-ECA5B2DBA570</gtr:id><gtr:title>Modeling idiosyncrasy: a novel animal model of drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A71D04FE-64AD-4E73-8E23-52580C266BBC"><gtr:id>A71D04FE-64AD-4E73-8E23-52580C266BBC</gtr:id><gtr:title>The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f45c4d8839ac0b19059ff2f93c9e4925"><gtr:id>f45c4d8839ac0b19059ff2f93c9e4925</gtr:id><gtr:otherNames>Senis YA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2440F185-D8F0-4819-A571-976138CCFE47"><gtr:id>2440F185-D8F0-4819-A571-976138CCFE47</gtr:id><gtr:title>PKCalpha regulates platelet granule secretion and thrombus formation in mice.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6957dcad8153745fcab7cb0fbd8e7248"><gtr:id>6957dcad8153745fcab7cb0fbd8e7248</gtr:id><gtr:otherNames>Konopatskaya O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4BC1FB9F-70FF-4BC6-BA6D-6F4DF4CF0A10"><gtr:id>4BC1FB9F-70FF-4BC6-BA6D-6F4DF4CF0A10</gtr:id><gtr:title>Distinct and overlapping functional roles of Src family kinases in mouse platelets.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c8d6737b2900d64897e3c80a301ffbe8"><gtr:id>c8d6737b2900d64897e3c80a301ffbe8</gtr:id><gtr:otherNames>S?verin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9BAE0CF5-56F1-4632-BBA6-1B8D48BC94CE"><gtr:id>9BAE0CF5-56F1-4632-BBA6-1B8D48BC94CE</gtr:id><gtr:title>MyosinIIa contractility is required for maintenance of platelet structure during spreading on collagen and contributes to thrombus stability.</gtr:title><gtr:parentPublicationTitle>Journal of thrombosis and haemostasis : JTH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5b54461412782f462ecfb14aedc7e8c5"><gtr:id>5b54461412782f462ecfb14aedc7e8c5</gtr:id><gtr:otherNames>Calaminus SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1538-7836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/210EA8FD-58CE-4B51-978F-3C542FCA77AE"><gtr:id>210EA8FD-58CE-4B51-978F-3C542FCA77AE</gtr:id><gtr:title>Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7edd426b5a61967abc9c0179a1fd40a9"><gtr:id>7edd426b5a61967abc9c0179a1fd40a9</gtr:id><gtr:otherNames>McCarty OJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2005-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/728D1FB5-AADA-4CF3-879A-4C8A739D5594"><gtr:id>728D1FB5-AADA-4CF3-879A-4C8A739D5594</gtr:id><gtr:title>Evaluation of serum lysyl oxidase as a blood test for colorectal cancer.</gtr:title><gtr:parentPublicationTitle>European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/34f318794f9294e886d3e13f3830ccfa"><gtr:id>34f318794f9294e886d3e13f3830ccfa</gtr:id><gtr:otherNames>Ward ST</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0748-7983</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EC7EF751-6F2A-4568-8E1E-B123605F446D"><gtr:id>EC7EF751-6F2A-4568-8E1E-B123605F446D</gtr:id><gtr:title>Critical role of FcR gamma-chain, LAT, PLCgamma2 and thrombin in arteriolar thrombus formation upon mild, laser-induced endothelial injury in vivo.</gtr:title><gtr:parentPublicationTitle>Microcirculation (New York, N.Y. : 1994)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8b51f6995168241d5785df1fc11f3dc4"><gtr:id>8b51f6995168241d5785df1fc11f3dc4</gtr:id><gtr:otherNames>Kalia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1073-9688</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1A6661A1-BD69-42AE-A014-2A52F28B4AB6"><gtr:id>1A6661A1-BD69-42AE-A014-2A52F28B4AB6</gtr:id><gtr:title>Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2F619339-35BB-447F-BC82-DFC2DC2E1016"><gtr:id>2F619339-35BB-447F-BC82-DFC2DC2E1016</gtr:id><gtr:title>Mechanisms of ANCA-mediated leukocyte-endothelial cell interactions in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b43ee83004007245b9bae49ebcc3ce51"><gtr:id>b43ee83004007245b9bae49ebcc3ce51</gtr:id><gtr:otherNames>Nolan SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/18F67F3A-5A4D-4405-983B-0AF90E7B5F15"><gtr:id>18F67F3A-5A4D-4405-983B-0AF90E7B5F15</gtr:id><gtr:title>A novel role for PECAM-1 (CD31) in regulating haematopoietic progenitor cell compartmentalization between the peripheral blood and bone marrow.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a8815e62a6f3fd63500acb52e99dbbeb"><gtr:id>a8815e62a6f3fd63500acb52e99dbbeb</gtr:id><gtr:otherNames>Ross EA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0300102</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>93C4699B-9E5C-4982-9CCC-EFD5B9712D6E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.6  Resources and infrastructure (aetiology)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>